New episode alert! 🔍 Curious about the future of Chronic Spontaneous Urticaria (CSU) treatment? There are exciting new medications on the horizon! 🌟
In our latest podcast episode, we dive deep into the future of CSU treatment with Dr. Matthew Zirwas (@bexleydermresearch). Whether you’re exploring new options for your CSU or just curious about new therapies, this episode is packed with insights you won’t want to miss!
Here’s what we cover:
💉 When to start biologics like Xolair (omalizumab) for hives
🆕 New treatments: Dupixent, Remibrutinib, and Barzolvolimab
🔍 How these treatments work: Understanding the impact on mast cells
🧠 And learn if they are getting closer to understanding the underlying cause of CSU!
✨ Tune in and discover the latest advancements that could change the way CSU is managed.
Did you miss the previous episodes in the series? Check out:
1️⃣ Understanding Chronic Spontaneous Urticaria
2️⃣ Diagnosing Chronic Spontaneous Urticaria
3️⃣ Treating Chronic Spontaneous Urticaria
4️⃣ Patient Interview: Living with Chronic Spontaneous Urticaria
5️⃣Busting Common CSU and Hive Myths
Listen on Spotify, Apple Podcast, or wherever you get your #podcasts
Produced in partnership with @allergyasthmahq. Thanks to #Novartis for sponsoring this episode and series.
#UrticariaTreatments #HivesTreatment #UrticariaMedication #ChronicHivesTreatment #XolairForHives #XolairUrticaria #OmalizumabUrticaria #CSUTreatment #HealthPodcast #SkinHealth #Allergy #Dermatology #AutoimmuneDisease #ChronicSpontaneousUrticaria #Hives #MentalHealth #CSU #ChronicUrticaria #Biologics #Xolair #Dupixent #Remibrutinib #Dermatology #SkinHealth #Podcast #HealthPodcast #AllergyAwareness #NewTreatments
23 авг 2024
